Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer

Journal of Clinical Oncology

Volumn 30, Issue 31, 2012, Pages 3841-3847

  Colombo, Nicoletta ^a   Kutarska, Elzbieta ^c   Dimopoulos, Meletios ^f   Bae, Duk Soo ^g   Rzepka Gorska, Izabella ^d   Bidzinski, Mariusz ^e   Scambia, Giovanni ^b   Engelholm, Svend Aage ^h   Joly, Florence ⁱ   Weber, Dirk ^j   El Hashimy, Mona ^j   Li, Jingjin ^j   Souami, Farida ^j   Wing, Patricia ^j   Engelholm, Silke ^h   Bamias, Aristotelis ^f   Schwartz, Peter ^k  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^c Centrum Onkologii Ziemi Lubelskej   (Poland)

^d POMERANIAN MEDICAL UNIVERSITY   (Poland)

^e INSTITUTE OF ONCOLOGY   (Poland)

^f UNIVERSITY OF ATHENS   (Greece)

^g Sungkyunkwan University School of Medicine   (South Korea)

^h Rigshospitalet   (Denmark)

ⁱ CENTRE FRANÇOIS BACLESSE   (France)

^j NOVARTIS PHARMA AG   (Switzerland)

^k YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPOTHILONE B; GEMCITABINE; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; TOPOTECAN;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ANEMIA; AREFLEXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BURNING SENSATION; CANCER CONTROL; CANCER PATIENT; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSESTHESIA; DYSPNEA; FATIGUE; FECES INCONTINENCE; FEMALE; FEVER; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERESTHESIA; HYPESTHESIA; HYPOKALEMIA; HYPOREFLEXIA; INSOMNIA; LETHARGY; MAJOR CLINICAL STUDY; MONONEUROPATHY; MOTOR NEUROPATHY; MOUTH ULCER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEURALGIA; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PAIN; PARESTHESIA; PERIPHERAL NEUROPATHY; PERITONEUM CANCER; PHASE 3 CLINICAL TRIAL; POLYNEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENT CANCER; SENSORIMOTOR NEUROPATHY; SENSORY DYSFUNCTION; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; UTERINE TUBE CARCINOMA; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; EPOTHILONES; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME;

EID: 84869109927     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.8082     Document Type: Article

References (22)

1. Ferlay J, Shin HR, Bray F, et al: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917, 2010
2. Jemal A, Siegel R, Xu J, et al: Cancer statistics, 2010. CA Cancer J Clin 60:277-300, 2010
3. National Comprehensive Cancer Network: The NCCN clinical practice guidelines in oncology ovarian cancer (version 2.2009). http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp
4. Yokoyama Y, Sato S, Fukushi Y, et al: Significance of multi-drug-resistant proteins in predicting chemotherapy response and prognosis in epithelial ovarian cancer. J Obstet Gynaecol Res 25:387-394, 1999 (Pubitemid 30028827)
5. Mozzetti S, Ferlini C, Concolino P, et al: Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 11:298-305, 2005 (Pubitemid 40075808)
6. Giannakakou P, Sackett DL, Kang YK, et al: Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272:17118-17125, 1997 (Pubitemid 27289821)
7. Kowalski RJ, Giannakakou P, Hamel E: Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (taxol(R)). J Biol Chem 272:2534-2541, 1997 (Pubitemid 27058547)
8. Bollag DM, McQueney PA, Zhu J, et al: Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 55:2325-2333, 1995
9. Altmann KH, Wartmann M, O'Reilly T: Epothilones and related structures: A new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim Biophys Acta 1470:M79-M91, 2000 (Pubitemid 30229922)
10. Ten Bokkel Huinink WW, Sufliarsky J, Smit WM, et al: Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: A phase I, open-label, dose-escalation study. J Clin Oncol 27:3097-3103, 2009
11. Strother R, Matei D: Pegylated liposomal doxorubicin in ovarian cancer. Ther Clin Risk Manag 5:639-650, 2009
12. Thigpen JT, Aghajanian CA, Alberts DS, et al: Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol Oncol 96:10-18, 2005 (Pubitemid 39612410)
13. Gordon AN, Fleagle JT, Guthrie D, et al: Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:3312-3322, 2001 (Pubitemid 32642183)
14. Mutch DG, Orlando M, Goss T, et al: Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 25: 2811-2818, 2007 (Pubitemid 47123191)
15. Therasse P, Arbuck SG, Eisenhauer EA, et al:New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
16. Rustin GJ: Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 21:187s-193s, 2003 (suppl)
17. Forster M, Kaye S, Oza A, et al: A phase Ib and pharmacokinetic trial of patupilone combined with carboplatin in patients with advanced cancer. Clin Cancer Res 13:4178-4184, 2007 (Pubitemid 47105981)
18. Gordon Lan KK, Demets DL: Discrete sequential boundaries for clinical trials. Biometrika 70:659-663, 1983
19. O'Brien PC, Fleming TR: A multiple testing procedure for clinical trials. Biometrics 35:549-556, 1979 (Pubitemid 10242750)
20. Cox DR: Regression models and life-tables. J R Stat Soc 34:187-220, 1972
21. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748, 1959
22. Vergote I, Finkler N, del Campo J, et al: Phase 3 randomised study of canfosfamide (telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. Eur J Cancer 45:2324-2332, 2009